Skip to main content
ZNTL
NASDAQ Life Sciences

Zentalis Reports Q2 2026 Results, Cash Runway into Late 2027, and FDA Alignment on Accelerated Approval Path for Azenosertib

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.8
Mkt Cap
$355.932M
52W Low
$1.212
52W High
$6.95
52W Position info
296% above low
Off High info
31% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ZNTL has more than doubled off its 52-week low of $1.212.

Summary

Zentalis reported Q2 2026 results with $174.6M in cash, runway into late 2027, and FDA alignment on an accelerated approval strategy for azenosertib. DENALI Part 2 enrollment is nearly complete, with topline data expected in 1H 2027.


Key Events · Earnings and Guidance · ZNTL

  • Q2 2026 Financial Results

    Net loss of $42.3 million; cash, cash equivalents, and marketable securities of $174.6 million as of June 30, 2026, providing runway into late 2027.

  • FDA Alignment on Accelerated Approval

    Type D meeting confirmed FDA has no objection to the 400mg QD 5:2 dose and DENALI Part 2 study population for potential accelerated approval in Cyclin E1-positive PROC.

  • DENALI Part 2 Enrollment and Timeline

    Enrollment complete in Parts 2a and 2b; Part 2c enrolling. Integrated topline readout expected in 1H 2027 to allow data maturation.

  • ASPENOVA Phase 3 Initiated

    First patient dosed in May 2026 in the confirmatory Phase 3 trial designed to support full approval.


Analysis · ZNTL · Life Sciences

Zentalis disclosed Q2 2026 financials with a net loss of $42.3 million and $174.6 million in cash, extending runway into late 2027. The FDA Type D meeting confirmed no objection to the selected dose and study population for potential accelerated approval of azenosertib in Cyclin E1-positive PROC. Enrollment in DENALI Part 2a and 2b is complete, with Part 2c enrolling, and topline data is expected in 1H 2027. The ASPENOVA confirmatory Phase 3 trial has dosed its first patient. These updates de-risk the regulatory path and provide a clear timeline to a pivotal catalyst, while the cash position supports operations through key milestones.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZNTL was trading at $4.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $355.9M. The 52-week trading range was $1.21 to $6.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZNTL - Latest Insights

ZNTL
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.40 info
Change: -$0.340 (-20%) info
Market Cap: $133.642M info
ZNTL
Oct 23, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.40 info
Change: -$0.910 (-39%) info
Market Cap: $133.642M info
ZNTL
Oct 19, 2026, 2:31 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $1.40 info
Change: -$0.885 (-39%) info
Market Cap: $133.642M info
ZNTL
Oct 18, 2026, 6:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.40 info
Change: -$0.710 (-34%) info
Market Cap: $133.642M info
ZNTL
Aug 19, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.82
Real-time Price: $1.40 info
Change: -$2.42 (-63%) info
Market Cap: $133.642M info